Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Lenalidomide clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Lenalidomide as a study intervention. Browse Lenalidomide recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 10:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
703
Shown on this page
12
Current sort
Recently updated
Therapy scope
Lenalidomide
Additional filters apply within this therapy.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this therapy

These controls apply only within Lenalidomide. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 265–276 of 703 matching trials for Lenalidomide.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Recruiting Early Phase 1 Interventional

VitD3 Supplementation in Patients With Multiple Myeloma

NCT05846880
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide, Maintenance Vitamin D, No maintenance Vitamin D
Drug
Lead sponsor
Amany Keruakous, MD, MS.
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 25, 2026, 10:06 AM EDT
Completed Phase 1Phase 2 Interventional Results available

To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

NCT03544281
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Belantamab mafodotin, Lenalidomide, Dexamethasone, Bortezomib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
12
States / cities
Birmingham, Alabama • Goodyear, Arizona • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 25, 2026, 10:06 AM EDT
Completed Phase 1 Interventional Results available

PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma

NCT03269136
View directory record Official record
Conditions
Multiple Myeloma
Interventions
PF-06863135 monotherapy IV or SC, PF-06863135 + dexamethasone, PF-06863135 + lenalidomide, PF-06863135 + pomalidomide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
32
States / cities
Encinitas, California • La Jolla, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 25, 2026, 10:06 AM EDT
Completed Phase 2 Interventional Results available

Ixazomib Rollover Study

NCT02924272
View directory record Official record
Conditions
Multiple Myeloma, Lymphoma, Amyloidosis
Interventions
Ixazomib
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
4
States / cities
Atlanta, Georgia • Hazard, Kentucky • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Oct 25, 2026, 10:06 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma

NCT04700176
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Daratumumab, Pomalidomide, All-trans retinoic acid, Dexamethasone
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Oct 25, 2026, 10:06 AM EDT
Completed Early Phase 1 Interventional

Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome

NCT02921893
View directory record Official record
Conditions
Plasmacytoma, POEMS Syndrome
Interventions
Dexamethasone, Ixazomib Citrate, Lenalidomide, Questionnaire Administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Oct 25, 2026, 10:06 AM EDT
Completed Phase 2 Interventional Results available

Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma

NCT02874742
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide, Bortezomib, Dexamethasone, Daratumumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
36
States / cities
Birmingham, Alabama • Duarte, California • La Jolla, California + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 25, 2026, 10:06 AM EDT
Completed Phase 2 Interventional Results available

Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

NCT01718743
View directory record Official record
Conditions
Hematopoietic Cell Transplantation Recipient, Plasma Cell Myeloma
Interventions
Ixazomib Citrate, Lenalidomide, Questionnaire Administration
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 25, 2026, 10:06 AM EDT
Active, not recruiting Phase 2 Interventional

Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma

NCT04782687
View directory record Official record
Conditions
Multiple Myeloma, Myeloma Multiple, Kahler Disease, Myeloma, Plasma Cell, Myeloma-Multiple, Myelomatosis, Plasma Cell Myeloma
Interventions
Selinexor, Dexamethasone Oral, Daratumumab, Lenalidomide
Drug
Lead sponsor
US Oncology Research
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
10
States / cities
Tucson, Arizona • Denver, Colorado • Columbia, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Oct 25, 2026, 10:06 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma

NCT00670358
View directory record Official record
Conditions
Lymphoma
Interventions
pegfilgrastim, rituximab, cyclophosphamide, doxorubicin hydrochloride, lenalidomide, prednisone, vincristine sulfate, polymorphism analysis, laboratory biomarker analysis
Biological · Drug · Genetic + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2024
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 10, 2025 · Synced Oct 25, 2026, 10:06 AM EDT
Completed Phase 2 Interventional Results available

Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma

NCT01553149
View directory record Official record
Conditions
Neurofibromatosis Type 1, Recurrent Childhood Pilocytic Astrocytoma, Recurrent Childhood Visual Pathway Glioma
Interventions
Lenalidomide, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
113
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 90 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Oct 25, 2026, 10:06 AM EDT
Recruiting Early Phase 1 Interventional

Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma

NCT06209606
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Ruxolitinib Oral Tablet [Jakafi], Lenalidomide, Methylprednisolone
Drug
Lead sponsor
Oncotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
West Hollywood, California
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Oct 25, 2026, 10:06 AM EDT

About this Lenalidomide clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Lenalidomide as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Lenalidomide.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Lenalidomide.